About Ambrx
Ambrx is a company based in San Diego (United States) founded in 2003 was acquired by Johnson & Johnson in January 2024.. Ambrx has raised $345.9 million across 6 funding rounds from investors including Fidelity Investments, Johnson & Johnson and Merck. The company has 79 employees as of December 31, 2022. Ambrx offers products and services including ARX788, ARX517, and ARX305. Ambrx operates in a competitive market with competitors including Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others.
- Headquarter San Diego, United States
- Employees 79 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ambrx, Inc.
-
Annual Revenue
$7.4 M-1as on Dec 31, 2022
-
Net Profit
$-78 M-15as on Dec 31, 2022
-
EBITDA
$-76.4 M-19as on Dec 31, 2022
-
Total Equity Funding
$345.9 M (USD)
in 6 rounds
-
Latest Funding Round
$200 M (USD), Series E
Nov 09, 2020
-
Investors
Fidelity Investments
& 22 more
-
Employee Count
79
as on Dec 31, 2022
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ambrx
Ambrx offers a comprehensive portfolio of products and services, including ARX788, ARX517, and ARX305. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets cancer with stable, site-specific conjugation for effective treatment
Focuses on advanced prostate cancer through enhanced protein engineering
Develops conjugates for potential oncology applications in clinical settings
Unlock access to complete
Unlock access to complete
Funding Insights of Ambrx
Ambrx has successfully raised a total of $345.9M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $200 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series E — $200.0M
-
First Round
First Round
(01 Oct 2003)
- Investors Count 20
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series E - Ambrx | Valuation | Fidelity Investments | |
| Aug, 2016 | Amount | Series E - Ambrx | Valuation | Apricot Capital | |
| Mar, 2009 | Amount | Series D - Ambrx | Valuation | Merck |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ambrx
Ambrx has secured backing from 23 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Johnson & Johnson and Merck. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Late-stage life sciences investments are managed via VC and PE.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ambrx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ambrx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ambrx Comparisons
Competitors of Ambrx
Ambrx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Denali Therapeutics, C4 Therapeutics, Erasca and Revolution Medicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ambrx
Frequently Asked Questions about Ambrx
When was Ambrx founded?
Ambrx was founded in 2003.
Where is Ambrx located?
Ambrx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Ambrx a funded company?
Ambrx is a funded company, having raised a total of $345.9M across 6 funding rounds to date. The company's 1st funding round was a Series D of $10M, raised on Oct 01, 2003.
How many employees does Ambrx have?
As of Dec 31, 2022, the latest employee count at Ambrx is 79.
What is the annual revenue of Ambrx?
Annual revenue of Ambrx is $7.4M as on Dec 31, 2022.
What does Ambrx do?
Developer of Antibody-drug conjugates to treat cancers, metabolic disorders, and cardiovascular disorders. The company has developed Engineered Precision Biologics (EPBs) by using proprietary genetic code technology to produce antibody-drug conjugates (ADCs) and immuno-oncology conjugates (IOCs) for treating cancers. The product pipeline includes ARX788 an anti-HER2 ADC currently being studied in breast cancer, gastric cancer, and other solid tumors, ARX517 for prostate cancer, and more. They have developed immuno-oncology conjugates for NASH, heart failure, and prostate cancer.
Who are the top competitors of Ambrx?
Ambrx's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Ambrx offer?
Ambrx offers ARX788, ARX517, and ARX305.
Who are Ambrx's investors?
Ambrx has 23 investors. Key investors include Fidelity Investments, Johnson & Johnson, Merck, WuXi AppTec, and BlackRock.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.